Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer
The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in patients with hormone receptor-positive, HER2-negative breast cancer ...